Anti-Mouse PD-1 Antibody (RMP1-14) is an IgG2a antibody inhibitor against mouse PD-1 and can block PD-1/PD-L1 signaling.

PD-1/PD-L1:4.05 μg/mL, PD-1/PD-L1:1.99 μg/mL

Method: To study the antitumor activity of Anti-Mouse PD-1 Antibody, mice were subcutaneously injected with MC38 (1×10^6) or B16-hCXCR4 (5×10^5). Two weeks later, tumor-bearing mice were intraperitoneally (ip) treated with anti-PD-1 mouse antibody [RMP1-14] (5 mg/kg, twice a week for 2 weeks), Pep R (2 mg/kg, 5 days a week for 2 weeks), or both.
Result: In the MC38 tumor-bearing mouse model, treatment with the anti-mouse PD-1 antibody in combination with Pep R significantly inhibited tumor growth. Compared with Pep R monotherapy, the relative tumor volume (RTV) in the combination therapy group was reduced by approximately 2.67-fold (p=0.038), indicating that the PD-1 blocking antibody RMP1-14 enhances the antitumor efficacy of the combination therapy. ^[1]

RMP1-14

Mouse

Immobilized Mouse PD-1 Protein (His) (TMPY-00996) at 1 μg/mL can bind Anti-Mouse PD-1 Antibody (RMP1-14). The EC50 is 22.030 ng/mL.

Monoclonal

Unconjugated